Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies

Shihori Tanabe; Sabina Quader; Horacio Cabral; Ryuichi Ono

doi:10.3389/fphar.2020.00904

Frontiers in Pharmacology (Jun 2020)

Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies

Shihori Tanabe,
Sabina Quader,
Horacio Cabral,
Ryuichi Ono

Affiliations

Shihori Tanabe: Division of Risk Assessment, Center for Biological Safety and Research (CBSR), National Institute of Health Science (NIHS), Kawasaki, Japan
Sabina Quader: Innovation Centre of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, Kawasaki, Japan
Horacio Cabral: Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan
Ryuichi Ono: Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research (CBSR), National Institute of Health Science (NIHS), Kawasaki, Japan

DOI: https://doi.org/10.3389/fphar.2020.00904
Journal volume & issue: Vol. 11

Abstract

Read online

The mechanism of epithelial-mesenchymal transition (EMT) consists of the cellular phenotypic transition from epithelial to mesenchymal status. The cells exhibiting EMT exist in cancer stem cell (CSC) population, which is involved in drug resistance. CSCs demonstrating EMT feature remain after cancer treatment, which leads to drug resistance, recurrence, metastasis and malignancy of cancer. In this context, the recent advance of nanotechnology in the medical application has ascended the possibility to target CSCs using nanomedicines. In this review article, we focused on the mechanism of CSCs and EMT, especially into the signaling pathways in EMT, regulation of EMT and CSCs by microRNAs and nanomedicine-based approaches to target CSCs.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords